GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Check-Cap Ltd (NAS:CHEK) » Definitions » Debt-to-EBITDA

Check-Cap (Check-Cap) Debt-to-EBITDA

: -0.00 (As of Sep. 2023)
View and export this data going back to 2015. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Check-Cap's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.03 Mil. Check-Cap's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Check-Cap's annualized EBITDA for the quarter that ended in Sep. 2023 was $-11.45 Mil. Check-Cap's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Check-Cap's Debt-to-EBITDA or its related term are showing as below:

CHEK's Debt-to-EBITDA is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.78
* Ranked among companies with meaningful Debt-to-EBITDA only.

Check-Cap Debt-to-EBITDA Historical Data

The historical data trend for Check-Cap's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Check-Cap Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.03 -0.03 -0.07 -0.05

Check-Cap Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.08 -0.05 - -

Competitive Comparison

For the Diagnostics & Research subindustry, Check-Cap's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Check-Cap Debt-to-EBITDA Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Check-Cap's Debt-to-EBITDA falls into.



Check-Cap Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Check-Cap's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.337 + 0.627) / -18.692
=-0.05

Check-Cap's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.03 + 0) / -11.452
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Check-Cap  (NAS:CHEK) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Check-Cap Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Check-Cap's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Check-Cap (Check-Cap) Business Description

Traded in Other Exchanges
Address
29 Abba Hushi Avenue, Check-Cap Building, P.O. Box 1271, Isfiya, ISR, 3009000
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.